Carcinogenesis Advance Access first published online on May 6, 2004
This version published online on May 27, 2004
Carcinogenesis, doi:10.1093/carcin/bgh182
© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 GlaxoSmithKline Pharmaceuticals, RTP, NC
* To whom correspondence should be addressed. E-mail: Debie.J.Hoivik{at}gsk.com.
There is little primate risk factor data in the literature evaluating the relationship between proposed mechanisms of PPAR agonist-induced hepatocarcinogenesis at clinically relevant therapeutic exposures. These studies were conducted to characterize the hepatic effects of fenofibrate and ciprofibrate in the cynomolgus monkey. Male cynomolgus monkeys were given fenofibrate (250, 1250 or 2500 mg/kg/day) or ciprofibrate (3, 30, 150 or 400 mg/kg/day) for up to 15 days. The highest doses used were approximately 4 times (fenofibrate) and 9.4 times (ciprofibrate) the human therapeutic exposure for these agents based on AUC (area under the curve). For both compounds, there was a treatment-related increase in liver weight and periportal hepatocellular hypertrophy, which was related to increases in peroxisomes (up to 2.8 times controls) and mitochondria (up to 2.5 times controls). An increase in smooth endoplasmic reticulum likely contributed to the hypertrophy. There was no indication of cell proliferation as determined by the number of mitotic figures and this was confirmed by evaluating cell proliferation by immunohistochemical staining for the Ki-67 antigen. Consistent with the findings by light microscopy, there was no treatment-related effect on the level of mRNA for proteins known to be involved in the control of hepatocyte cell division or apoptosis (e.g. P21, Cyclin D1, PCNA, CDKN1A). Furthermore, there was minimal indication of oxidative stress. Thus, there was no evidence of lipofuscin accumulation, and there was no remarkable increase in the mRNA levels for most proteins known to respond to oxidative stress (e.g. catalase, glutathione peroxidase). A mild induction in the mRNA levels of cellular
Revised April 5, 2004
Accepted April 27, 2004
CARCINOGENESIS
Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys
2 Upper Merion, PA
Abstract 
-oxidation and detoxification enzymes (e.g. acyl CoA oxidase, thioredoxin reductase) was observed. Collectively, the data from these studies suggest that the primate responds to PPAR
agonists in a manner that is different from the rodent suggesting that the primate may be refractory to PPAR-induced hepatocarcinogenesis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Ohta, N. Masutomi, N. Tsutsui, T. Sakairi, M. Mitchell, M. V. Milburn, J. A. Ryals, K. D. Beebe, and L. Guo Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats Toxicol Pathol, June 1, 2009; 37(4): 521 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Liu, A. D. Patterson, Z. Yang, X. Zhang, W. Liu, F. Qiu, H. Sun, K. W. Krausz, J. R. Idle, F. J. Gonzalez, et al. Fenofibrate Metabolism in the Cynomolgus Monkey using Ultraperformance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics Drug Metab. Dispos., June 1, 2009; 37(6): 1157 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Gopinathan, D. B. Hannon, J. M. Peters, and J. P. Vanden Heuvel Regulation of Peroxisome Proliferator-Activated Receptor-{alpha} by MDM2 Toxicol. Sci., March 1, 2009; 108(1): 48 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Woods, J. P. Vanden Heuvel, and I. Rusyn Genomic Profiling in Nuclear Receptor-Mediated Toxicity Toxicol Pathol, June 1, 2007; 35(4): 474 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Guo, R. A. Jolly, B. W. Halstead, T. K. Baker, J. P. Stutz, M. Huffman, J. N. Calley, A. West, H. Gao, G. H. Searfoss, et al. Underlying Mechanisms of Pharmacology and Toxicity of a Novel PPAR Agonist Revealed Using Rodent and Canine Hepatocytes Toxicol. Sci., April 1, 2007; 96(2): 294 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Frazier, R. Thomas, M. Scicchitano, R. Mirabile, R. Boyce, D. Zimmerman, E. Grygielko, J. Nold, A.-C. DeGouville, S. Huet, et al. Inhibition of ALK5 Signaling Induces Physeal Dysplasia in Rats Toxicol Pathol, February 1, 2007; 35(2): 284 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Morimura, C. Cheung, J. M. Ward, J. K. Reddy, and F. J. Gonzalez Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor {alpha} to Wy-14,643-induced liver tumorigenesis Carcinogenesis, May 1, 2006; 27(5): 1074 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Cariello, E. H. Romach, H. M. Colton, H. Ni, L. Yoon, J. G. Falls, W. Casey, D. Creech, S. P. Anderson, G. R. Benavides, et al. Gene Expression Profiling of the PPAR-alpha Agonist Ciprofibrate in the Cynomolgus Monkey Liver Toxicol. Sci., November 1, 2005; 88(1): 250 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Torrey, J. A. Campbell, D. J. Hoivik, R. T. Miller, J. S. Allen, P. C. Mann, K. Selinger, D. Rickert, P. M. Savina, and M. J. Santostefano Evaluation of the Carcinogenic Potential of Clofibrate in the p53+/- Mouse International Journal of Toxicology, September 1, 2005; 24(5): 289 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Torrey, H. G. Wall, J. A. Campbell, P. Kwanyuen, D. J. Hoivik, R. T. Miller, J. S. Allen, M. J. Jayo, K. Selinger, P. M. Savina, et al. Evaluation of the Carcinogenic Potential of Clofibrate in FVB/Tg.AC Mouse After Oral Administration--Part I International Journal of Toxicology, September 1, 2005; 24(5): 313 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Nesfield, T. C. Williams, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, D. Rickert, and M. J. Santostefano Evaluation of the Carcinogenic Potential of Clofibrate in the Neonatal Mouse International Journal of Toxicology, September 1, 2005; 24(5): 341 - 348. [Abstract] [Full Text] [PDF]
|
|